Allogene Therapeutics, Inc.
US ˙ NasdaqGS ˙ US0197701065

Introduction

This page provides a comprehensive analysis of the known insider trading history of Franz B Humer. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Franz B Humer has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:ALLO / Allogene Therapeutics, Inc. Director 307,507
US:C / Citigroup Inc. Director 2,669
US:KITE / Kite Pharma, Inc. Director 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Franz B Humer. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ALLO / Allogene Therapeutics, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ALLO / Allogene Therapeutics, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2018-10-15 ALLO Humer Franz B 30,000 18.0000 30,000 18.0000 540,000 22 33.3000 459,000 85.00

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ALLO / Allogene Therapeutics, Inc. Insider Trades
Insider Sales ALLO / Allogene Therapeutics, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ALLO / Allogene Therapeutics, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
2024-12-05 ALLO Humer Franz B 9,221 2.1600 9,221 2.1600 19,917 160 0.9528 -11,131 -55.89
2024-05-30 ALLO Humer Franz B 11,200 2.3376 11,200 2.3376 26,181

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ALLO / Allogene Therapeutics, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Franz B Humer as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2024-12-09 2024-12-05 4 ALLO Allogene Therapeutics, Inc.
Common Stock
S - Sale -9,221 307,507 -2.91 2.16 -19,917 664,215
2024-06-07 2024-06-05 4 ALLO Allogene Therapeutics, Inc.
Common Stock
A - Award 61,475 316,728 24.08
2024-06-03 2024-05-30 4 ALLO Allogene Therapeutics, Inc.
Common Stock
S - Sale -11,200 255,253 -4.20 2.34 -26,181 596,679
2023-06-15 2023-06-13 4 ALLO Allogene Therapeutics, Inc.
Common Stock
A - Award 74,561 266,453 38.86
2022-06-17 2022-06-15 4 ALLO Allogene Therapeutics, Inc.
Common Stock
A - Award 44,178 191,892 29.91
2021-06-11 2021-06-10 4 ALLO Allogene Therapeutics, Inc.
Common Stock
A - Award 16,498 147,714 12.57
2020-06-09 2020-06-05 4 ALLO Allogene Therapeutics, Inc.
Common Stock
A - Award 9,969 131,216 8.22
2019-06-24 2019-06-06 4 ALLO Allogene Therapeutics, Inc.
Common Stock
A - Award 16,377 121,247 15.62
2019-04-02 2019-04-01 4 C CITIGROUP INC
Common Stock
A - Award 15 2,669 0.55 63.05 926 168,269
2019-04-02 2019-04-01 4 C CITIGROUP INC
Common Stock
A - Award 151 21,304 0.72 63.05 9,542 1,343,217
2019-02-15 2019-02-14 4 C CITIGROUP INC
Common Stock
A - Award 601 2,654 29.25
2019-01-04 2019-01-02 4 C CITIGROUP INC
Common Stock
A - Award 36 4,693 0.78 58.01 2,101 272,251
2019-01-04 2019-01-02 4 C CITIGROUP INC
Common Stock
A - Award 143 18,513 0.78 58.01 8,287 1,074,027
2018-10-17 2018-10-15 4 ALLO Allogene Therapeutics, Inc.
Series A Convertible Preferred Stock
C - Conversion -14,261 0 -100.00
2018-10-17 2018-10-15 4 ALLO Allogene Therapeutics, Inc.
Common Stock
C - Conversion 74,870 104,870 249.57
2018-10-17 2018-10-15 4 ALLO Allogene Therapeutics, Inc.
Common Stock
P - Purchase 30,000 30,000 18.00 540,000 540,000
2018-10-03 2018-10-01 4 C CITIGROUP INC
Common Stock
A - Award 30 4,657 0.64 70.35 2,086 327,576
2018-10-03 2018-10-01 4 C CITIGROUP INC
Common Stock
A - Award 117 18,370 0.64 70.35 8,231 1,292,283
2018-07-02 2018-07-01 4 C CITIGROUP INC
Common Stock
A - Award 22 4,627 0.47 67.57 1,476 312,645
2018-07-02 2018-07-01 4 C CITIGROUP INC
Common Stock
A - Award 86 18,253 0.47 67.57 5,824 1,233,381
2018-04-03 2018-04-01 4 C CITIGROUP INC
Common Stock
A - Award 11 4,605 0.24 74.44 826 342,787
2018-04-03 2018-04-01 4 C CITIGROUP INC
Common Stock
A - Award 78 18,167 0.43 74.44 5,797 1,352,293
2018-02-16 2018-02-15 4 C CITIGROUP INC
Common Stock
A - Award 2,015 4,594 78.13
2018-01-03 2018-01-02 4 C CITIGROUP INC
Common Stock
A - Award 28 6,715 0.42 75.63 2,142 507,863
2018-01-03 2018-01-02 4 C CITIGROUP INC
Common Stock
A - Award 59 13,954 0.42 75.63 4,451 1,055,362
2017-10-05 2017-10-03 4 KITE Kite Pharma, Inc.
Director Stock Option (Right to Buy)
D - Sale to Issuer -8,810 0 -100.00 88.79 -782,240
2017-10-05 2017-10-03 4 KITE Kite Pharma, Inc.
Director Stock Option (Right to Buy)
D - Sale to Issuer -7,000 0 -100.00 129.13 -903,910
2017-10-05 2017-10-03 4 KITE Kite Pharma, Inc.
Director Stock Option (Right to Buy)
D - Sale to Issuer -20,000 0 -100.00 123.88 -2,477,600
2017-10-05 2017-10-03 4 KITE Kite Pharma, Inc.
Common Stock
D - Sale to Issuer -1,807 0 -100.00
2017-10-05 2017-10-03 4 KITE Kite Pharma, Inc.
Common Stock
U - Other -4,624 1,807 -71.90 180.00 -832,320 325,260
2017-10-03 2017-10-01 4 C CITIGROUP INC
Common Stock
A - Award 31 6,686 0.47 67.95 2,132 454,316
2017-10-03 2017-10-01 4 C CITIGROUP INC
Common Stock
A - Award 65 13,895 0.47 67.95 4,430 944,089
2017-07-05 2017-07-01 4 C CITIGROUP INC
Common Stock
A - Award 17 6,655 0.26 62.77 1,063 417,751
2017-07-05 2017-07-01 4 C CITIGROUP INC
Common Stock
A - Award 35 13,829 0.26 62.77 2,209 868,105
2017-06-22 2017-06-20 4 KITE Kite Pharma, Inc.
Director Stock Option (Right to Buy)
A - Award 8,810 8,810
2017-06-22 2017-06-20 4 KITE Kite Pharma, Inc.
Common Stock
A - Award 2,410 6,431 59.94
2017-04-04 2017-04-01 4 C CITIGROUP INC
Common Stock
A - Award 11 6,638 0.16 61.11 653 405,635
2017-04-04 2017-04-01 4 C CITIGROUP INC
Common Stock
A - Award 36 13,794 0.26 61.11 2,202 842,928
2017-02-17 2017-02-16 4 C CITIGROUP INC
Common Stock
A - Award 2,550 6,627 62.52
2017-01-05 2017-01-03 4 C CITIGROUP INC
Common Stock
A - Award 29 10,759 0.27 58.65 1,717 631,027
2017-01-05 2017-01-03 4 C CITIGROUP INC
Common Stock
A - Award 19 7,077 0.27 58.65 1,130 415,116
2016-10-04 2016-10-01 4 C CITIGROUP INC
Common Stock
A - Award 36 10,729 0.34 47.31 1,711 507,649
2016-10-04 2016-10-01 4 C CITIGROUP INC
Common Stock
A - Award 24 7,058 0.34 47.31 1,126 333,953
2016-07-06 2016-07-01 4 C CITIGROUP INC
Common Stock
A - Award 12 10,693 0.11 45.02 534 481,376
2016-07-06 2016-07-01 4 C CITIGROUP INC
Common Stock
A - Award 8 7,034 0.11 45.02 351 316,669
2016-06-03 2016-06-01 4 KITE Kite Pharma, Inc.
Director Stock Option (Right to Buy)
A - Award 7,000 7,000
2016-06-03 2016-06-01 4 KITE Kite Pharma, Inc.
Common Stock
A - Award 1,950 4,021 94.16
2016-04-05 2016-04-01 4 C CITIGROUP INC
Common Stock
A - Award 13 10,681 0.12 42.10 534 449,673
2016-04-05 2016-04-01 4 C CITIGROUP INC
Common Stock
A - Award 4 7,027 0.05 42.10 149 295,814
2016-03-24 2016-03-10 4 KITE Kite Pharma, Inc.
Common Stock
A - Award 2,071 2,071
2016-02-18 2016-02-16 4 C CITIGROUP INC
Common Stock
A - Award 4,048 7,023 136.12
2016-01-05 2016-01-01 4 C CITIGROUP INC
Common Stock
A - Award 7 7,637 0.09 53.31 378 407,097
2016-01-05 2016-01-01 4 C CITIGROUP INC
Common Stock
A - Award 6 6,006 0.09 53.31 299 320,168
2015-10-05 2015-10-01 4 C CITIGROUP INC
Common Stock
A - Award 7 7,630 0.10 51.28 379 391,208
2015-10-05 2015-10-01 4 C CITIGROUP INC
Common Stock
A - Award 6 6,000 0.10 51.28 297 307,671
2015-09-17 2015-09-09 4 KITE Kite Pharma, Inc.
Stock Option Grant (Right to Buy)
A - Award 20,000 20,000
2015-07-06 2015-07-01 4 C CITIGROUP INC
Common Stock
A - Award 5 5,995 0.09 55.94 296 335,314
2015-07-06 2015-07-01 4 C CITIGROUP INC
Common Stock
A - Award 7 7,622 0.09 55.94 380 426,355
2015-04-03 2015-04-01 4 C CITIGROUP INC
Common Stock
A - Award 1 5,989 0.01 53.16 30 318,415
2015-04-03 2015-04-01 4 C CITIGROUP INC
Common Stock
A - Award 1 7,615 0.02 53.16 74 404,865
2015-02-20 2015-02-18 4 C CITIGROUP INC
Common Stock
A - Award 2,966 5,989 98.13
2015-01-05 2015-01-01 4 C CITIGROUP INC
Common Stock
A - Award 1 4,195 0.02 54.88 42 230,208
2015-01-05 2015-01-01 4 C CITIGROUP INC
Common Stock
A - Award 1 6,442 0.02 54.88 60 353,497
2014-10-03 2014-10-01 4 C CITIGROUP INC
Common Stock
A - Award 1 4,194 0.02 52.10 42 218,526
2014-10-03 2014-10-01 4 C CITIGROUP INC
Common Stock
A - Award 1 6,440 0.02 52.10 63 335,563
2014-07-03 2014-07-01 4 C CITIGROUP INC
Common Stock
A - Award 1 4,193 0.02 48.50 42 203,367
2014-07-03 2014-07-01 4 C CITIGROUP INC
Common Stock
A - Award 1 6,439 0.02 48.50 63 312,287
2014-04-03 2014-04-01 4 C CITIGROUP INC
Common Stock
A - Award 2 10,630 0.02 48.54 102 515,978
2014-02-20 2014-02-18 4 C CITIGROUP INC
Common Stock
A - Award 3,020 10,628 39.70
2014-01-03 2014-01-01 4 C CITIGROUP INC
Common Stock
A - Award 1 7,608 0.02 51.58 72 392,426
2013-10-03 2013-10-01 4 C CITIGROUP INC
Common Stock
A - Award 2 7,606 0.02 50.17 75 381,621
2013-07-03 2013-07-01 4 C CITIGROUP INC
Common Stock
A - Award 2 7,605 0.02 50.65 76 385,173
2013-07-03 2013-07-01 4 C CITIGROUP INC
Common Stock
A - Award 2 7,605 0.02 50.65 76 385,173
2013-07-03 2013-07-01 4 C CITIGROUP INC
Common Stock
A - Award 2 7,605 0.02 50.65 76 385,173
2013-04-03 2013-04-01 4 C CITIGROUP INC
Common Stock
A - Award 1 7,603 0.01 45.39 42 345,111
2013-02-21 2013-02-19 4 C CITIGROUP INC
Common Stock
A - Award 3,414 7,602 81.52
2013-01-03 2013-01-01 4 C CITIGROUP INC
Common Stock
A - Award 1 4,188 0.03 36.62 40 153,372
2012-10-03 2012-10-01 4 C CITIGROUP INC
Common Stock
A - Award 1 4,187 0.03 32.35 39 135,453
2012-07-03 2012-07-01 4 C CITIGROUP INC
Common Stock
A - Award 4,186 4,186
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)